We are live on ! Find out more
NGNE icon

Neurogene
NGNE

39 hedge funds and large institutions have $10.5M invested in Neurogene in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $8.66M → $10.5M (+$1.88M)

0.24% less ownership

Funds ownership: 2% → 1.76% (-0.24%)

13% less funds holding

Funds holding: 45 → 39 (-6)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

Holders
39
Holders Change
-6
Holders Change %
-13.33%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
15
Closed
11
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$10K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$152K
2
LCM
Lynx1 Capital Management
Puerto Rico
+$80.4K
3
MA
MYDA Advisors
New York
+$23.4K
4
BCM
BML Capital Management
Indiana
+$13.9K
5
US Bancorp
US Bancorp
Minnesota
+$13.7K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$475K
2
Bank of America
Bank of America
North Carolina
-$274K
3
Barclays
Barclays
United Kingdom
-$262K
4
Renaissance Technologies
Renaissance Technologies
New York
-$163K
5
JP Morgan Chase
JP Morgan Chase
New York
-$42.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$11.9K +$9.96K +850 New
UBS Group
27
UBS Group
Switzerland
$10.4K -$4.03K -344 -32%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$10.1K – – –
CSS
29
Cubist Systematic Strategies
Connecticut
$9.41K +$7.88K +672 New
PCM
30
PenderFund Capital Management
British Columbia, Canada
$6K +$3.93K +335 New
Wells Fargo
31
Wells Fargo
California
$5.76K +$12 +1 +0.2%
Barclays
32
Barclays
United Kingdom
$3.7K -$262K -22,348 -99%
Federated Hermes
33
Federated Hermes
Pennsylvania
$1.33K -$1.52K -130 -58%
Osaic Holdings
34
Osaic Holdings
Arizona
$1.08K – – –
Group One Trading
35
Group One Trading
Illinois
$1.05K -$293 -25 -25%
TC
36
Truvestments Capital
Florida
$648 – – –
JP Morgan Chase
37
JP Morgan Chase
New York
– -$42.6K -3,637 -100%
Jane Street
38
Jane Street
New York
– -$30.9K -3,033 Closed
SCM
39
Sio Capital Management
New York
– -$19.5K -1,916 Closed
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
– -$13.5K -1,328 Closed
E
41
Ergoteles
New York
– -$12.2K -1,202 Closed
Acadian Asset Management
42
Acadian Asset Management
Massachusetts
– -$10K -1,059 Closed
Nomura Holdings
43
Nomura Holdings
Japan
– -$8K -812 Closed
KAS
44
Kestra Advisory Services
Texas
– -$6.79K -667 Closed
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
– -$5.43K -523 Closed
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
– -$5 -518 Closed
TLP
47
Tri Locum Partners
New York
– -$5K -512 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– -$1.84K -157 -84%
Citigroup
49
Citigroup
New York
– -$137 -14 Closed
1
2

NGNE Hedge Fund Activity: Q1 2023 in Review

39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2023, worth a combined $10.5M — up 22% from $8.66M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NGNE and 5 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Morgan Stanley, adding an estimated $152K. The largest seller was Millennium Management, cutting an estimated $475K.

  • 39 institutional investors held Neurogene (NGNE) as of Q1 2023, down from 45 in Q4 2022.
  • Funds reported $10.5M of Neurogene stock for Q1 2023, up 22% quarter-over-quarter.
  • 5 funds opened new Neurogene positions in Q1 2023 and 11 closed out, a net change of -6 holders.
  • The largest Neurogene buyer in Q1 2023 was Morgan Stanley, an estimated $152K added.
  • The largest Neurogene seller in Q1 2023 was Millennium Management, an estimated $475K sold.

Based on aggregated 13F filings for Q1 2023.